Perspective Therapeutics Stock (AMEX: CATX)

Perspective Therapeutics

PERSPECTIVE THERAPEUTICS INC

Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.

Medical.doctor.medicine.illness.hospital

Analyst Color

Biotech

News

Health Care

Initiation

Analyst Ratings

Trading Ideas

General

CATX

H.C. Wainwright &amp; Co. initiates a Buy rating on Perspective Therapeutics, citing promising cancer radiotherapy assets.

Perspective Therapeutics&#39; Cancer-Focused Radiotherapy Portfolio Has Upside Potentional, Says Analyst

cancer

Movers

Perspective Therapeutics shares interim results for [212Pb]VMT-α-NET trial, showing promising safety, stable disease cases, and anti-tumor activity.

Perspective Therapeutics Touts Encouraging Updated Data From Gastrointestinal Cancer Trial, Stock Soars

Wall Street US stocks

Earnings

Equities

Eurozone

Commodities

Intraday Update

Markets

KURA

NVDA

PYXS

QUBT

SNOW

Dow Jumps Over 100 Points; Nvidia Posts Upbeat Earnings

Perspective Therapeutics, Inc. Common Stock

Perspective Therapeutics Inc

Press Releases

Perspective Therapeutics Announces First Patient Dosed with [212Pb]VMT01 in Combination with Nivolumab in a Phase 1/2a Study of MC1R-Positive Metastatic Melanoma

Perspective Therapeutics Provides Recent Business Highlights and Reports Full Year 2024 Results

Perspective Therapeutics to Participate in Upcoming April Investor Conferences

Perspective Therapeutics Announces First Patient Dosed with [212Pb]VMT01 Monotherapy at 1.5 mCi in a Phase 1/2a Study of MC1R-Positive Metastatic Melanoma

Perspective Therapeutics to Provide Business Highlights and Report First Quarter 2025 Financial Results

Perspective Therapeutics Announces Acceptance of VMT-α-NET and VMT01 Data for Presentation at the 2025 ASCO Annual Meeting

Perspective Therapeutics Announces First Patient Dosed with PSV359 in a Phase 1/2a Study in Patients with FAP-α Positive Solid Tumors

Perspective Therapeutics to Participate in Upcoming May Investor Conferences

Perspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2025 Results

Perspective Therapeutics Highlights Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-α-NET at the 2025 ASCO Annual Meeting

Candel Therapeutics

Cardiff Oncology

Cargo Therapeutics

DBV Technologies S.A. - American Depositary Shares

DBV Technologies

Design Therapeutics

4D Molecular Therapeutics, Inc. - Common Stock

4D Molecular Therapeutics

Foghorn Therapeutics

Genfit

I-MAB

Immutep Limited - American Depositary Shares

Immutep

Inhibrx Biosciences

Inozyme Pharma

Kodiak Sciences

Lexicon Pharmaceuticals, Inc. - Common Stock

Lexicon Pharmaceuticals

Monopar Therapeutics

Prime Medicine

Cartesian Therapeutics, Inc. - Common Stock

Cartesian Therapeutics

Silence Therapeutics Plc - American Depository Share

Silence Therapeutics

Instil Bio

TriSalus Life Sciences, Inc. - Common Stock

TriSalus Life Sciences

Tonix Pharmaceuticals Holding Corp. - Common Stock

Tonix Pharmaceuticals

Tevogen Bio Holdings

Vanda Pharmaceuticals Inc. - Common Stock

Vanda Pharmaceuticals

Voyager Therapeutics, Inc. - Common Stock

Voyager Therapeutics

Y-mAbs Therapeutics

RBC Capital

Truist Securities

HC Wainwright & Co.

Wedbush

Comments

Perspective Therapeutics

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell